|
03 Jun 2007 |
Clinical Data Presented on Pilot Pharmacokinetic Study of Oral Azacitidine
|
|
03 Jun 2007 |
Study Supports Activity of GEMZAR(R) (Gemcitabine HC1 for Injection) in the Treatment of Early-Stage Breast Cancer
|
|
03 Jun 2007 |
New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer
|
|
02 Jun 2007 |
Serenex announces initiation of Phase 1 trial for oral Hsp90 inhibitor, SNX-5422
|
|
02 Jun 2007 |
EntreMed's Aurora Kinase inhibitor induces tumor regression in preclinical models
|
|
02 Jun 2007 |
Termination of Development of Fixed Dose Combination Product of Actos(R) + TAK-536
|
|
02 Jun 2007 |
Indigo Pharmaceuticals, Inc. Signs License Agreement for INDI-702, a Drug for the Treatment of Arteriosclerosis Obliterans, With Nissan Chemical Industries and Taisho Pharmaceutical Co.
|
|
02 Jun 2007 |
Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin(R) in Recurrent, Metastatic Non-Small Cell Lung Cancer
|
|
02 Jun 2007 |
Thallion announces publication of eco-4601 phase I/II Clinical data at ASCO
|
|
02 Jun 2007 |
ZIO-101 Oral Capsule Clears FDA Review for Phase I Study
|
|
02 Jun 2007 |
Arrowhead subsidiary, Insert, publishes interim Phase I data from human clinical trials for new cancer drug
|
|
02 Jun 2007 |
Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
|
|
02 Jun 2007 |
OXiGENE Abstracts Published in ASCO Program
|
|
01 Jun 2007 |
AtheroGenics Announces Business Plan to Focus on Advancing AGI-1067 in Diabetes
|
|
01 Jun 2007 |
LifeCycle Pharma Announces Positive Phase I Clinical Results
|
|
01 Jun 2007 |
Skyepharma PLC - Twice daily ZYFLO CR(TM) (zileuton) extended-release tablets approved by the FDA for asthma
|
|
01 Jun 2007 |
New research confirms the benefit of extended-release dipyridamole plus ASA for preventing recurrent stroke in low- and high-risk patients
|
|
01 Jun 2007 |
Progenics and Wyeth Announce FDA Has Accepted For Filing the New Drug Application for Subcutaneous Methylnaltrexone
|
|
01 Jun 2007 |
AVANIR Receives FDA Approval for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
|
|
01 Jun 2007 |
ISTA Pharmaceuticals Announces Positive Preliminary Results from Ecabet Sodium Phase IIb Study
|
|
01 Jun 2007 |
Labopharm Receives Second Approvable Letter from FDA for Once-Daily Tramadol
|
|
01 Jun 2007 |
Allos Therapeutics Initiates Phase I/II Study of PDX and Gemcitabine in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
|
|
01 Jun 2007 |
Valeant Pharmaceuticals to Initiate Study of Retigabine for Pain Associated with Post-Herpetic Neuralgia
|
|
31 May 2007 |
Exelixis Initiates Phase II Trial of XL647 in NSCLC Patients Who Have Previously Benefited From EGFR Inhibitors or Have the T790M Mutant Form of EGFR
|
|
31 May 2007 |
Novacea and Schering-Plough Enter into Worldwide Development and Commercialization Agreement for Asentar, a Novel Treatment for Prostate Cancer
|
